Oxford Nanopore expanded clinical adoption of rapid nanopore sequencing for CNS tumor classification through Norway’s MATRIX program and the country’s national precision diagnostics infrastructure (InPreD). The rollout starts after Phase 1 evaluation of 50 CNS tumor samples showed “strong agreement” with established diagnostic methods. The program will integrate nanopore-based classification into clinical workflows, including laboratory information system integration, bioinformatics validation, and updates to diagnostic pathways. In phase two, the effort begins at Oslo University Hospital, Haukeland University Hospital, and St. Olavs Hospital, with plans for future expansion. Oxford Nanopore also said it will extend collaboration with MATRIX toward broader genomic and multiomics use cases, including somatic and germline variant detection, copy number benchmarking, single-cell transcriptomics, and genome-wide methylation. For biotech-facing diagnostics, the move highlights how sequencing platforms are moving from research tools toward routine clinical decision support under EU IVDR documentation requirements.